CY1108929T1 - Αλατα ή συμπλοκα δοτων μεθυλιου με φυτικο οξυ ή τα παραγωγα αυτου και μεθοδος για τη συνθεση αυτων - Google Patents

Αλατα ή συμπλοκα δοτων μεθυλιου με φυτικο οξυ ή τα παραγωγα αυτου και μεθοδος για τη συνθεση αυτων

Info

Publication number
CY1108929T1
CY1108929T1 CY20091100356T CY091100356T CY1108929T1 CY 1108929 T1 CY1108929 T1 CY 1108929T1 CY 20091100356 T CY20091100356 T CY 20091100356T CY 091100356 T CY091100356 T CY 091100356T CY 1108929 T1 CY1108929 T1 CY 1108929T1
Authority
CY
Cyprus
Prior art keywords
salts
donors
synthesis
derivatives
compounds
Prior art date
Application number
CY20091100356T
Other languages
Greek (el)
English (en)
Inventor
Luca Maria De
Original Assignee
Luca Maria De
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Luca Maria De filed Critical Luca Maria De
Publication of CY1108929T1 publication Critical patent/CY1108929T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Seasonings (AREA)
CY20091100356T 2005-06-30 2009-03-26 Αλατα ή συμπλοκα δοτων μεθυλιου με φυτικο οξυ ή τα παραγωγα αυτου και μεθοδος για τη συνθεση αυτων CY1108929T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000344A ITRM20050344A1 (it) 2005-06-30 2005-06-30 Sali o complessi di sostanze metil-donatrici con acido fitico o suoi derivati e relativo metodo di sintesi.
EP06766355A EP1896489B1 (en) 2005-06-30 2006-06-23 Salts or complexes of methyl donors with phytic acid or its derivatives and method for the synthesis thereof

Publications (1)

Publication Number Publication Date
CY1108929T1 true CY1108929T1 (el) 2014-07-02

Family

ID=39033793

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100356T CY1108929T1 (el) 2005-06-30 2009-03-26 Αλατα ή συμπλοκα δοτων μεθυλιου με φυτικο οξυ ή τα παραγωγα αυτου και μεθοδος για τη συνθεση αυτων

Country Status (14)

Country Link
US (1) US8293254B2 (enExample)
EP (1) EP1896489B1 (enExample)
JP (2) JP4589999B2 (enExample)
KR (1) KR101346974B1 (enExample)
AT (1) ATE419256T1 (enExample)
CY (1) CY1108929T1 (enExample)
DE (1) DE602006004588D1 (enExample)
DK (1) DK1896489T3 (enExample)
ES (1) ES2320489T3 (enExample)
IT (1) ITRM20050344A1 (enExample)
PL (1) PL1896489T3 (enExample)
PT (1) PT1896489E (enExample)
SI (1) SI1896489T1 (enExample)
WO (1) WO2007004244A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20060026A1 (it) * 2006-01-10 2007-07-11 Truffini & Regge Farmaceutici Srl Composizioni per uso rale a base di s-adenosilmetionina e processo per il loro ottenimento
ITMI20060629A1 (it) 2006-03-31 2007-10-01 Daniele Giovannone Composizioni solide orali a base di s-adenosilmetionina e processo per il loro ottenimento
WO2008004973A2 (en) 2006-07-07 2008-01-10 Telefonaktiebolaget Lm Ericsson (Publ) Resource allocation for co-existin networks
ITMI20071374A1 (it) * 2007-07-10 2009-01-11 Gnosis Spa Sali stabili di s-adenosilmetionina e processo per il loro ottenimento.
JP4598846B2 (ja) * 2008-07-14 2010-12-15 磐田化学工業株式会社 S−アデノシルメチオニン安定化のためのフィチン酸および/またはデキストリンを含む飲食用組成物
IT1393331B1 (it) * 2009-02-09 2012-04-20 Graal S R L Composizioni orosolubili e/o effervescenti contenenti almeno un sale di s-adenosilmetionina (same)
JP5573587B2 (ja) 2010-10-20 2014-08-20 株式会社デンソー 車両用回転電機
KR102186066B1 (ko) 2013-01-16 2020-12-04 허버트 샘-이 엘엘씨 S-아데노실-l-메티오닌의 안정한 인돌-3-프로피오네이트염
ES2486441B1 (es) * 2014-04-02 2015-06-11 Universitat De Les Illes Balears Preparaciones combinadas de acidificantes urinarios e inhibidores de la cristalización y su aplicación para el tratamiento o prevención de la litiasis renal fosfática o inducida por fosfato cálcico
WO2017040611A1 (en) * 2015-08-31 2017-03-09 Nutramax Laboratories, Inc. Compositions comprising magnolia, phellodendron, theanine and/or whey protein
IT201700074957A1 (it) * 2017-07-04 2019-01-04 Gnosis Spa Sale di (ss)-adenosil metionina con inositolo esafosfato e procedimento per ottenerlo
FR3068602B1 (fr) * 2017-07-10 2020-11-20 Guy Parc Nouveau traitement du cancer par une combinaison d'un derive phosphorique d'inositol et de chlorure de magnesium
EP3556398A1 (en) * 2018-04-16 2019-10-23 Croda Denmark A/S Phytates for use as a biomolecules delivery or adsorption system
JP2021046375A (ja) * 2019-09-19 2021-03-25 ポッカサッポロフード&ビバレッジ株式会社 β3アドレナリン受容体活性化剤
CN115572309B (zh) * 2022-09-20 2024-05-03 浙江工业大学 一种高效阻燃、抗熔滴的环境友好型阻燃剂

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2824869A (en) * 1954-08-04 1958-02-25 Bristol Lab Inc Salt of streptomycin and phytic acid
US3019226A (en) * 1959-04-10 1962-01-30 Olin Mathieson Piperazine salt of phytic acid
US3242235A (en) * 1963-06-13 1966-03-22 Squibb & Sons Inc Phytate salts of the tetracyclines
IE39517B1 (en) * 1973-06-27 1978-10-25 Bioresearch Sas Double salts of s-adenosyl-l-methhionine
IT1200589B (it) * 1985-02-14 1989-01-27 Gibipharma Spa Derivati naturali attivita farmagologica
JPH0215032A (ja) * 1988-07-01 1990-01-18 Sanwa Kagaku Kenkyusho Co Ltd 肝疾患治療、予防剤及び強肝機能性飲食、し好物
US5434144A (en) * 1994-03-04 1995-07-18 The Procter & Gamble Company Methods of using cyclic polyanionic polyol derivatives for regulating skin wrinkles
IT1318535B1 (it) * 2000-05-25 2003-08-27 Chementecno Srl Processo per la preparazione di sali farmaceuticamente accettabili di(ss,rs)-s-adenosil-l-metionina.
US20030069202A1 (en) * 2000-06-02 2003-04-10 Kern Kenneth Norman Compositions, kits, and methods for promoting defined health benefits
WO2002010177A1 (en) 2000-08-01 2002-02-07 Gmp Companies, Inc. Ammonium salts of inositol hexaphosphate and uses thereof
JP2002145783A (ja) * 2000-11-06 2002-05-22 Kohjin Co Ltd S−アデノシルメチオニンまたはその塩類を含有するカプセル製剤
US20030078231A1 (en) * 2001-06-22 2003-04-24 Wilburn Michael D. Orthomolecular sulpho-adenosylmethionine derivatives with antioxidant properties
WO2003087109A1 (en) * 2002-04-12 2003-10-23 Silbiotec Due S.A. Medicaments containing glycerophosphoinositol-4-phosphate derivatives
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
ES2323141T3 (es) * 2004-08-12 2009-07-07 Quest Pharmaceutical Services Composiciones farmaceuticas para el suministro por liberacion controlada de compuestos biologicamente activos.
US20060046982A1 (en) * 2004-08-26 2006-03-02 Waugh William H Orthomolecular medical use of L-citrulline for capillary endothelial protection and adjacent cell protection in neurodegenerative disease

Also Published As

Publication number Publication date
US20090175914A1 (en) 2009-07-09
EP1896489A1 (en) 2008-03-12
SI1896489T1 (sl) 2009-06-30
WO2007004244A1 (en) 2007-01-11
DK1896489T3 (da) 2009-04-20
PL1896489T3 (pl) 2009-06-30
KR20080028949A (ko) 2008-04-02
ATE419256T1 (de) 2009-01-15
ITRM20050344A1 (it) 2007-01-01
KR101346974B1 (ko) 2014-01-02
PT1896489E (pt) 2009-04-01
EP1896489B1 (en) 2008-12-31
ES2320489T3 (es) 2009-05-22
JP2010235616A (ja) 2010-10-21
US8293254B2 (en) 2012-10-23
JP5283659B2 (ja) 2013-09-04
JP4589999B2 (ja) 2010-12-01
DE602006004588D1 (de) 2009-02-12
JP2009500319A (ja) 2009-01-08

Similar Documents

Publication Publication Date Title
SI1896489T1 (sl) Soli ali kompleksi donorjev metilne skupine s fitinsko kislino ali njenimi derivati in postopek za njihovo sintezo
BR112021006229A2 (pt) composto, composição farmacêutica, e, método para tratamento de um câncer
BR112015021838A2 (pt) amatoxina, método de síntese, composição farmacêutica
CY1108529T1 (el) Νεα αζαδικυκλικα παραγωγα, μεθοδος παρασκευης τους και φαρμακευτικες συνθεσεις που τα περιεχουν
CY1116929T1 (el) Παραγωγα πυρρολο[2,3-d]πυριμιδινης ως αναστολεις πρωτεϊνικης κινασης β
CY1111045T1 (el) Μεθοδος παραγωγης ενος παραγωγου βενζιμιδαζολιου
UY28968A1 (es) (orto-fenil)-anilidas de ácido 1-metil-3-trifluorometil-pirazol-4-carboxílico y su uso como fungicida
CY1112237T1 (el) Παραγωγα 5-υδροξυ-βενζοθειαζολης που εχουν ενεργοτητα αγωνιστη βητα-2-αδρενοϋποδοχεα
ATE447564T1 (de) Zwischenprodukte für die herstellung von trans-5- chlor-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenzä , 3:6,7üoxepinoä4,5-cüpyrrol
CY1110034T1 (el) Παραγωγα 1,2,4,5-τετραϋδρο-3h-βενζαζεπινων, μεθοδος παρασκευης αυτων και οι φαρμακευτικες συνθεσεις που τα περιεχουν
WO2008076270A3 (en) Sulfide, sulfoxide and sulfone chalcone analogues, derivatives thereof and therapeutic uses thereof
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
CY1117461T1 (el) Παραγωγα κιναζολινοδιονης, παρασκευη αυτων και οι θεραπευτικες εφαρμογες τους
ATE493425T1 (de) Verfahren zur herstellung ortho-metallierter metallverbindungen
BRPI0519521A2 (pt) derivados de tieno-piridina como aumentadores alostÉricos gaba-b
CY1110541T1 (el) Φαρμακευτικα σκευασματα με βελτιωμενες φαρμακευτικες ιδιοτητες που περιεχουν βελτιωτικα γευσης
CY1111203T1 (el) 4-ανιλινοκινολινο-3-καρβοξαμιδια ως αναστολεις κινασης csf-1r
CO6420351A2 (es) Composiciones plaguicidas
AR058348A1 (es) Derivados de 1-aza-biciclo-nonano y composiciones farmaceuticas que los comprenden
EP2578587A4 (en) PYRAZOLE DERIVATIVES
WO2008016682A3 (en) Aryl vinyl sulfides, sulfones, sulfoxides and sulfonamides, derivatives thereof and therapeutic uses thereof
DE502007003531D1 (de) Verfahren zum herstellen von alkylaniliden aus halogenbenzolderivaten
EA200701817A1 (ru) Новые соли 6-гетероциклических замещенных производных гексагидрофенантридина
CL2019002499A1 (es) Protodescarboxilación catalizada por metales de transición de derivados de ácido a-halo-acrílico.
CY1109358T1 (el) Εκδοχο για την αναγωγη των ιοντων χρωμιου (vi) σε ιοντα χρωμιου (iii)